Fiorillo Benjamin P, Melton M Stephen, Nelsen Derek, Einhorn Lisa M
Department of Anesthesiology, Duke University Medical Center, DUMC 3094, Durham, NC 27710, USA.
J Clin Med. 2024 Dec 13;13(24):7586. doi: 10.3390/jcm13247586.
: In 2021, the Food and Drug Administration approved liposomal bupivacaine injectable suspension for single-dose infiltration in patients ≥ 6 years of age. Liposomal bupivacaine and bupivacaine hydrochloride admixtures may also be administered off-label for pediatric regional anesthesia including peripheral nerve blocks (PNBs). This single-injection, long-acting technique is not well described in pediatrics but may have benefits over traditional continuous catheter-based systems. The purpose of this investigation was to examine an adolescent cohort who received liposomal bupivacaine/bupivacaine hydrochloride PNBs for orthopedic surgery. : Patient, surgical, anesthetic, block characteristics, and post-anesthesia care unit (PACU) outcomes were retrospectively reviewed from February 2020 to June 2024. From February to December 2022, a short follow-up survey was conducted to assess post-discharge patient-reported outcomes. : There were 524 liposomal bupivacaine/bupivacaine hydrochloride PNBs (106 upper-extremity and 418 lower-extremity) performed in 374 patients with a mean (standard deviation, range) age of 16 (1.2, 11-17) years. Two unilateral PNBs were performed in 150 (40%) patients to ensure an adequate sensory neural blockade. The interscalene ( = 81, 15%) and adductor canal ( = 140, 27%) blocks were the most common upper- and lower-extremity PNBs, respectively. Intraoperatively, the majority of the cohort ( = 258, 69%) underwent monitored anesthesia care (MAC). No patient required conversion from MAC to general anesthesia due to pain. In PACU, 288 (77%) patients reported no pain. Mild and moderate pain were reported by 56 (15%) and 30 (8%) patients, respectively. No patients developed local anesthetic toxicity. The survey results ( = 66) indicate that the majority of patients (96%) were satisfied with block analgesia postoperatively. : Liposomal bupivacaine/bupivacaine hydrochloride PNBs were used successfully in adolescents undergoing a variety of orthopedic surgeries.
2021年,美国食品药品监督管理局批准脂质体布比卡因注射用混悬液用于6岁及以上患者的单剂量浸润麻醉。脂质体布比卡因和盐酸布比卡因混合剂也可用于儿科区域麻醉的非标签用药,包括外周神经阻滞(PNB)。这种单次注射的长效技术在儿科中描述较少,但可能比传统的基于连续导管的系统更具优势。本研究的目的是调查一组接受脂质体布比卡因/盐酸布比卡因外周神经阻滞进行骨科手术的青少年。
回顾性分析了2020年2月至2024年6月期间患者、手术、麻醉、阻滞特征及麻醉后护理单元(PACU)的结果。2022年2月至12月,进行了一项短期随访调查,以评估出院后患者报告的结果。
374例患者共进行了524次脂质体布比卡因/盐酸布比卡因外周神经阻滞(106例上肢阻滞和418例下肢阻滞),患者平均(标准差,范围)年龄为16(1.2,11 - 17)岁。150例(40%)患者进行了两次单侧外周神经阻滞,以确保充分的感觉神经阻滞。肌间沟阻滞(n = 81,15%)和收肌管阻滞(n = 140,27%)分别是最常见的上肢和下肢外周神经阻滞。术中,大多数患者(n = 258,69%)接受了监护麻醉(MAC)。没有患者因疼痛需要从监护麻醉转为全身麻醉。在麻醉后护理单元,288例(77%)患者报告无疼痛。分别有56例(15%)和30例(8%)患者报告有轻度和中度疼痛。没有患者发生局部麻醉药毒性反应。调查结果(n = 66)表明,大多数患者(96%)对术后的阻滞镇痛满意。
脂质体布比卡因/盐酸布比卡因外周神经阻滞成功用于接受各种骨科手术的青少年。